Brief: Zealand Pharma Initiates Global Phase 3 ZUPREME Program For Petrelintide
22/09/2026 16:01
BRIEF-Zealand Pharma Initiates Global Phase 3 ZUPREME Program For Petrelintide Sept 22 (Reuters) - Zealand Pharma A/S ZELA.CO:
INITIATES GLOBAL PHASE 3 ZUPREME PROGRAM FOR PETRELINTIDE
PHASE 3A ZUPREME PROGRAM CONSISTS OF THREE TRIALS FOR PETRELINTIDE MONOTHERAPY
PRIMARY ENDPOINT IS PERCENTAGE CHANGE IN BODY WEIGHT FROM BASELINE TO WEEK 64
Source text: ID:nGNE61cy2W
Further company coverage: ZELA.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Zealand Pharma A/S
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)